Email Updates

Search form

You are here

HIV Vaccine

There is momentum and promise in the search for an HIV vaccine.

An effective preventive HIV vaccine would teach the body how to prevent HIV infection. Vaccines are the most powerful public health tools available—and an HIV vaccine would play a powerful role in ensuring the end to the AIDS epidemic.

While effective vaccines remain years away, there are more reasons for hope than ever before. Researchers are expanding on the result of a 2009 trial that showed, for the first time, that a vaccine can reduce the risk of HIV infection. They’re also pursuing groundbreaking research with other novel vaccine strategies, including broadly neutralizing antibodies that target a wide range of HIV strains. At the same time, there is also exciting work in efforts to understand if and how to cure HIV in people who are already infected. The timeline for this work is long and uncertain. Here, too, advocacy is needed to sustain momentum.

Today’s momentum depends on sustained funding. Policy makers and funders around the world must have the courage to sustain vital HIV vaccine research for years to come, and advocates must keep the pressure on them to maintain their commitments.

What We're Reading

In the future, MTBVAC could be further developed as a vector to express optimized HIV immunogens and utilized in prime-boost vaccination protocols along with new boosting agents. It could, furthermore, be used as a novel mycobacterial vaccine platform for infectious diseases such as malaria, whooping cough and other tropical diseases, to prime protective immune responses shortly after birth.

January 30, 2019
Molecular Therapy: Methods & Clinical Development

For decades, it was thought an effective vaccine would be developed in just a year or two (reports claimed this as early as the 1980s). Instead, failures have pushed scientists to embrace multi-injection vaccines. Now, a new study has renewed researchers’ optimism about the potential for a single-shot vaccine.

February 14, 2019
HIV Plus Mag

In a step forward in the search for an HIV vaccine, Professor Denis Burton and colleagues from the Scripps Institute in La Jolla, California have manufactured an HIV vaccine that, with just one shot, induced six out of 12 monkeys to make antibodies that significantly delayed infection or (in two cases) even prevented it.

January 2, 2019
Antibody Related Research, HIV Vaccine
aidsmap
Subscribe to RSS - HIV Vaccine